Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
CAMBRIDGE, Mass, USA, and TOKYO, Japan, February 28, 2022 – Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights...
TOKYO and BOTHELL, Wash. – February 28, 2022 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use...
TOKYO and BOTHELL, Wash. – February 14, 2022 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the initial results from Cohort H of the EV-103 trial investigating...
TOKYO, February 8, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the following Top Management members effective from...
TOKYO, Feb. 7, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive interim safety data from FORTIS, the Phase I/II clinical trial evaluating AT845, an investigational adeno-associated virus (AAV) gene...
TOKYO, February 2, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares pursuant...
TOKYO and BOTHELL, Wash., December 18, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced...
TOKYO and BOTHELL, Wash. – December 17, 2021 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use...
TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today applied for selection of the “Prime Market” segment of the Tokyo Stock Exchange, Inc. (“TSE”) as its listing market as determined at the Board...
TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., “Dyno”) today announced an option and license agreement...
TOKYO, Dec. 1, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new investigational data in acute myeloid leukemia (AML) and sickle cell disease at the 63rd American Society...
TOKYO and Hennigsdorf, Germany, November 15, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pantherna Therapeutics GmbH (CEO: Klaus Giese, Ph.D., “Pantherna”) today announced that the companies...
TOKYO, October 20, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for the “2021 Award for Excellence in Corporate Disclosure”...
TOKYO and BOTHELL, Wash. – October 12, 2021 – Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103...
TOKYO, October 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) begin using biomass-based plastics made from plant-derived materials in blister packages as the primary packaging for pharmaceutical products...
TOKYO, October 1, 2021 - Juntendo University (President: Hajime Arai, M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the parties have established, inside Juntendo University Graduate School...
TOKYO and BOTHELL, Wash. – Sept. 27, 2021 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PADCEV®...
TOKYO and Sendai, Miyagi, September 24, 2021 - Tohoku University (President; Hideo Ohno, “Tohoku University”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) have established the second phase of comprehensive industry-...
TOKYO, September 22, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will present 12-week results (S-13) from the pivotal Phase 3 SKYLIGHT 2™ clinical trial of fezolinetant for the treatment of moderate to severe vasomotor...
TOKYO , September 21, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has begun the pilot sales of an exercise support service, Fit-eNce HomeTM, designed under the supervision of...
TOKYO and NEW YORK, September 17, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today ahead of the European Society for Medical Oncology (ESMO) Congress 2021 that XTANDI®...
TOKYO, September 14, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on September 1, passed away on September 9...
TOKYO, OSAKA, and IWATE, September 2nd, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ), Nitto Denko Corporation (TSE: 6988, President; Hideo Takasaki, “Nitto”), and M. Heart Co., Ltd. (President and CEO: Yoshimi...
TOKYO, September 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients...
TOKYO, August 31, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D.) today announced that the personnel changes as below...
TOKYO, August 20, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZOTM...
TOKYO, August 6, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will change its research organization as of October 1, 2021 as follows...
TOKYO, Japan, and Haifa, Israel, July 30, 2021 - Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced a worldwide strategic collaboration...
TOKYO and Iwate, July 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and M. Heart Co., Ltd. (Headquarters: Iwate, President and CEO: Yoshimi Mizunuma, "M. Heart") launched "MYHOLTER II", a software for the holter...
CAMBRIDGE, Mass, USA, and TOKYO, Japan, July 13, 2021 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae...
TOKYO, July 13, 2021 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for 10 consecutive years, as a company that is performing excellent initiatives in the areas of ESG...
TOKYO and BOTHELL, Wash.– July 9, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted PADCEV® (enfortumab vedotin-ejfv)...
TOKYO, June 25, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for Medicinal Products for Human Use (CHMP)...
TOKYO, June 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it has decided to terminate the development of the DNA vaccine ASP0892, which is currently in Phase 1 study for peanut allergy...
TOKYO, June 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Astellas and Cheplapharm Arzneimittel GmbH (“Cheplapharm”) have enterd into an Asset Purchase Agreement, under which Astellas will...
TOKYO, June 8, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) virtual congress...
TOKYO, June 3, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) is constantly reviewing its management resource allocation in order to respond flexibly to rapid changes in the business environment and strengthen...
TOKYO, May 26, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced its new Corporate Strategic Plan 2021 (“CSP2021”) for fiscal years 2021 through 2025...
TOKYO & BOTHELL, Wash. – May 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced updated results from two clinical trials examining PADCEV® (enfortumab vedotin-ejfv)...
TOKYO, May 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021...
TOKYO, May 14, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced Japan's Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company’s New Drug Application (NDA)...
TOKYO and Kyoto, May 13, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Kyoto University Innovation Capital Co., Ltd. (President and CEO; Ko Kusumi, “KYOTO-iCAP”) have established a strategic alliance...
TOKYO, May 12, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) today announced that at the meeting of the Board of Directors held today...
TOKYO, May 4, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the European Commission (EC) has approved an additional indication for the oral once-daily therapy XTANDITM (enzalutamide)...
TOKYO, April 27, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it booked an impairment loss in the fourth quarter of the fiscal year ended March 31, 2021 (April 1, 2020 to March 31, 2021)...
TOKYO, April 27, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at a meeting of its Board of Directors held today...
TOKYO and BOTHELL, Wash. – April 19, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) filed two supplemental Biologics License...
TOKYO, April 5, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TOA EIYO Ltd. (President: Atsuo Takahashi, Ph.D., “TOA EIYO”) today announced that the both companies have agreed to terminate the distribution agreement...
TOKYO, April 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) annouced that Astellas and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, “Viatris”) have agreed to end the co-promotion of a...
TOKYO and New York, March 31, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug...
TOKYO, March 31, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it will further integrate its wholly owned subsidiary, Audentes Therapeutics, and establish “Astellas Gene Therapies” within the organization...
TOKYO, March 30, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that a Phase 3 confirmatory trial of XOSPATA® (gilteritinib) in patients with relapsed (disease that has returned) or refractory (resistant to...
TOKYO, March 29, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...
TOKYO, March 26, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) has entered into two joint research agreements today to maximize the value of medications using AI and statistical methods. One agreement is with the...
TOKYO, March 26, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) approved Myrbetriq® (mirabegron extended-release tablets) for the treatment...
TOKYO and BOTHELL, Wash. – March 26, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorization application (MAA) for enfortumab vedotin was...
TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin...
TOKYO, February 26, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) announced that at the meeting of the Board of Directors held today...
TOKYO, February 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 pivotal SKYLIGHT 1™ and SKYLIGHT 2™ clinical trials for fezolinetant, an investigational...
TOKYO and BOTHELL, Wash. – Feb. 18, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications...
TOKYO and BOTHELL, Wash. – February 12, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced results from the second cohort (cohort 2) of patients in the pivotal phase 2 single-arm...
TOKYO and BOTHELL, Wash. – February 12, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV®...
TOKYO, February 4, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has granted conditional approval to XOSPATA® (gilteritinib) for the treatment...
TOKYO, February 4, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced the following Executive Comittee Standing Members effective from...
TOKYO, February 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that its subsidiary, Astellas Pharma Europe Ltd. (“Astellas Europe”), and Tolmar International Limited (“Tolmar”) have entered into an agreement...
TOKYO, January 25, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that construction of new manufacturing lines for aseptic drug products utilizing new modalities and technologies has commenced...
TOKYO, January 13, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) has entered into a research collaboration for molecular targeted radiotherapies with Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM, Chief...
TOKYO, January 6, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) accepted priority review for its New Drug Application (NDA) for mirabegron for oral...
TOKYO, December 25, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that its wholly owned subsidiary Audentes Therapeutics, Inc. (“Audentes” ) has been notified that the U.S. Food and Drug...
TOKYO, December 21, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that a Phase 3 trial of XOSPATA® (gilteritinib) plus azacitidine versus azacitidine alone in newly diagnosed FLT3 mutation-positive (FLT3mut+)...
TOKYO, December 17, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) expressed its support for the recommendation of the Task Force on Climate-related Financial Disclosures*1 (TCFD), established by the Financial...
TOKYO, December 16, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that Astellas will open a new logistics center for the Kyushu area in Kitakyushu City, Fukuoka Prefecture...
PITTSBURGH, PA and TOKYO, December 7, 2020 – KaliVir Immunotherapeutics LLC (CEO: Helena Chaye, Ph.D., J.D., “KaliVir”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that they entered...
TOKYO, December 7, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, “Viatris”) announced that the two companies have agreed to end the joint...
TOKYO, November 27, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the subsidiary Astellas Pharma Europe Ltd. (“Astellas Europe”) and Tillotts Pharma AG (“Tillotts”) have entered into an...
TOKYO, November 27, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) today announced that Japan’s Ministry of Health, Labour and...
TOKYO, November 16, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the virtual 62nd American Society of Hematology...
TOKYO, November 11, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) announced that it has decided today, to absorb and merge (“the Merger”) our wholly owned subsidiaries, Astellas Pharma Tech...
TOKYO, November 6, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has approved XTANDI® (enzalutamide soft capsules)...
TOKYO October 30, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it has completed the acquisition of Iota Biosciences, Inc. (“iota”), a start-up company focused on the bioelectronics field, located...
TOKYO, October 28, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) announced today that the United States (“U.S.”) Food and Drug Administration (FDA) has granted Fast Track designation based on nonclinical...
TOKYO, October 20, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of...
TOKYO, OCTOBER 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, “Astellas”) today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society...
TOKYO and Berkeley, CA., October 15, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Iota Biosciences, Inc. (Co-founders and Co-CEOs: Michel Maharbiz, Ph.D. and Jose Carmena, Ph.D., “iota”) announced today...
TOKYO and BOTHELL, Wash. -- October 12, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the second cohort of patients in the pivotal phase...
TOKYO, September 28, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced findings from two Real-World Evidence (RWE) studies and a qualitative sleep survey that underscore the prevalence of...
TOKYO and PITTSBURGH, PA, September 24, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and University of Pittsburgh (Chancellor: Patrick Gallagher, Ph.D., “Pittsburgh”) have entered into a research collaboration...
TOKYO, September 23, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) has signed an agreement with two research centers at the University of Tokyo (President: Makoto Gonokami, Ph.D.): The Institute for Life Science...
TOKYO and BOTHELL, Wash. -- September 18, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv)...
TOKYO, August 24, 2020 - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it will start accepting advance applications and taking reservations for its exercise support service Fit-eNce®1, which encourages...
TOKYO, July 22, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH)...
TOKYO, July 20, 2020 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for ninth consecutive year. Astellas was recognized for its strong performance especially...
TOKYO, June 8, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the Phase 3 DOLOMITES study, evaluating the efficacy and safety of roxadustat compared with darbepoetin alfa for the treatment...
TOKYO, June 5, 2020 - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) developed science-based exercise programs in cooperation with the City of Yokohama, Kanagawa Prefecture (Kanagawa, Mayor: Fumiko Hayashi, "City of...
TOKYO, May 29, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved XTANDI® (enzalutamide), an oral androgen receptor...
NEW YORK and TOKYO, May 29, 2020 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated...
TOKYO and San Francisco, May 21, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) today announced the marketing authorization application
TOKYO, May 20, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) today announced that the meeting of the Board of Directors held today passed...
TOKYO and CAMBRIDGE, Mass., April 28, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Harvard University (President: Lawrence S. Bacow, J.D., M.P.P., Ph.D., “Harvard”) have established a three-year strategic research...
TOKYO, April 27, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at a meeting of its Board of Directors held today...
Follow us
